Cargando…

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study

BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory skin disease for which biologics are effective treatments. Dose reduction (DR) of the first generation biologics seems a promising way for more efficient use of expensive biologics. A substantial part of patients on tumor necrosis facto...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Schoot, Lara S., van den Reek, Juul M. P. A., Grine, Lynda, Schots, Lisa, Kievit, Wietske, Lambert, Jo L. W., de Jong, Elke M. G. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520290/ https://www.ncbi.nlm.nih.gov/pubmed/34656148 http://dx.doi.org/10.1186/s13063-021-05681-z

Ejemplares similares

Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial
por: Atalay, Selma, et al.
Publicado: (2017)

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
por: van der Schoot, Lara S., et al.
Publicado: (2022)

Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
por: Busard, Celine, et al.
Publicado: (2017)

Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
por: Busard, Celine, et al.
Publicado: (2017)

Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis
por: Soenen, Rani, et al.
Publicado: (2022)

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice
por: ATALAY, Selma, et al.
Publicado: (2021)

The Effects of Modified Intermittent Fasting in Psoriasis (MANGO): Protocol for a Two-Arm Pilot Randomized Controlled Open Cross-over Study
por: Grine, Lynda, et al.
Publicado: (2022)

Data‐driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine
por: van der Schoot, L. S., et al.
Publicado: (2021)

Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene: results from a multicentre study of four European psoriasis cohorts
por: van Vugt, L.J., et al.
Publicado: (2019)

Il ne faut jurer de rien : proverbe /
por: Musset, Alfred de, 1810-1857
Publicado: (1936)

Ne' a Doberdo', ne' in Germania il protosincrotrone da 300 GeV
Publicado: (1970)

Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study
por: ATALAY, Selma, et al.
Publicado: (2020)

Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER): Protocol for a Longitudinal Observational Study
por: van Hal, Tamara W, et al.
Publicado: (2021)

Supercollisioneur : Puis ils ne furent plus que sept...
Publicado: (1988)

Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study
por: Smits, L J T, et al.
Publicado: (2020)

Discovery of Psoriatic Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) Study: A Prospective Observational Cohort
por: VAN HAL, Tamara W., et al.
Publicado: (2022)

The Effect of Lifestyle Changes on Disease Severity and Quality of Life in Patients with Plaque Psoriasis: A Narrative Review
por: van Acht, Maartje R, et al.
Publicado: (2022)

Ils ne mouraient pas tous mais tous étaient frappés
por: Pezé, Marie
Publicado: (2010)

Patients’ perspectives towards biologic dose reduction in psoriasis: a qualitative study
por: van der Schoot, L. S., et al.
Publicado: (2023)

Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study)
por: Koek, Mayke B G, et al.
Publicado: (2009)

The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
por: Brembilla, Nicolo Costantino, et al.
Publicado: (2018)

The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis
por: Madonna, Stefania, et al.
Publicado: (2019)

Re-evaluation of IL-10 signaling reveals novel insights on the contribution of the intracellular domain of the IL-10R2 chain
por: Wilbers, Ruud H. P., et al.
Publicado: (2017)

A non-clinical comparative study of IL-23 antibodies in psoriasis
por: Zhou, Li, et al.
Publicado: (2021)

The role of IL-23 in the immunopathogenesis of psoriasis
por: Meglio, Paola Di, et al.
Publicado: (2010)

Regulation of IL-22BP in psoriasis
por: Voglis, Stefanos, et al.
Publicado: (2018)

The Role of IL-17 Cytokines in Psoriasis
por: Mosca, Megan, et al.
Publicado: (2021)

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis
por: Glatt, Sophie, et al.
Publicado: (2017)

IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-Type Psoriasis in Brazilian Patients
por: de Oliveira, Priscilla Stela Santana, et al.
Publicado: (2015)

Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN
por: Keermann, Maris, et al.
Publicado: (2015)

Le neutrino de tau ne fait-il pas le poids?
Publicado: (1991)

Ne dites pas à Dieu ce qu'il doit faire
por: De Closets, F
Publicado: (2004)

Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide
por: van Muijen, M. E., et al.
Publicado: (2021)

Comment on: Drug Survival of IL‑12/23, IL‑17 and IL‑23 Inhibitors for Psoriasis Treatment: A Retrospective Multi‑Country, Multicentric Cohort Study
por: Borg, Emma, et al.
Publicado: (2021)

Targeting IL-23 in psoriasis: current perspectives
por: Fotiadou, Christina, et al.
Publicado: (2018)

The contribution of IL-17 to the development of autoimmunity in psoriasis
por: Furue, Masutaka, et al.
Publicado: (2019)

An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis
por: Kutwin, Magdalena, et al.
Publicado: (2021)

Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors
por: Huang, Yu-Huei, et al.
Publicado: (2023)

Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity
por: Arican, Ozer, et al.
Publicado: (2005)

Predicting treatment success with biologics in psoriasis
por: van den Reek, J.M.P.A.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hg3qqvh7j04udbh8daie95hrac